Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10655388 | 0.94 | MAPT (0.36) | MAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL5730528 | 0.85 | — | — | |
| SCHEMBL5729906 | 0.83 | TSHR (0.30) | — | |
| SCHEMBL8661196 | 0.75 | MAPT (0.35) | MAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL5965358 | 0.74 | — | — | |
| SCHEMBL2139630 | 0.73 | — | — | |
| Trolamine SCHEMBL11688308 | 0.73 | MAPT (0.37) | MAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL1461493 | 0.73 | CA12 (0.36) | KDM4E | |
| SCHEMBL2575881 | 0.72 | — | — | |
| SCHEMBL64496 | 0.71 | CYP1A2 (0.44) | MAPTKDM4EALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820258-A | Corrosion inhibitor and preparation method and application thereof | 深圳飞扬骏研新材料股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117820258-A | Corrosion inhibitor and preparation method and application thereof | 深圳飞扬骏研新材料股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-8980242-B2 | Aliphatic prodrug linker | ASCENDIS PHARMA GMBH (DK) | 2015-03-17 | — | — | US | disclosed |
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | ASCENDIS PHARMA GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-7332515-B2 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070123528-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | US | disclosed |
| US-7166636-B2 | Type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, or hyperglucagonemia; methyl (S)-5-{1-[(5-chloro-1H-indol-2-ylcarbonyl)amino]-2-phenylethyl}oxazole-4-carboxylate; amidation by reacting the 2-carboxyindole and a 1,2-diphenylethylamine | ASTRAZENECA AB (SE) | 2007-01-23 | — | — | US | disclosed |
| EP-1483271-B1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-7138415-B2 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-11-21 | — | — | US | disclosed |
| US-7122567-B2 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050130963-A1 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRA ZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1492788-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| EP-1483240-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1483271-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074517-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074531-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074484-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | PYGL, PYGM, PYGB | MAPT 3484/4885KDM4E 3404/4885ALOX15 4292/4885 |
| US-20050130963-A1 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | GYS1, PYGL, GYS2 | MAPT 2918/4885KDM4E 3065/4885ALOX15 1985/4885 |
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | PAICS, AADAC, TK1 | MAPT 986/4885KDM4E 2936/4885ALOX15 2151/4885 |
| US-20070123528-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | PYGL, PYGM, PYGB | MAPT 886/4885KDM4E 1586/4885ALOX15 2373/4885 |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | PYGL, GYS1, CBR3 | MAPT 3821/4885KDM4E 3240/4885ALOX15 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.